Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials

References

• Fidalgo Rodríguez JL, Dynarowicz-Latka P, Miñones Conde J. Structure of unsaturated fatty acids in 2D system. Colloids Surf B Biointerf. 2017;158:634–642.
   PubMed Web of Science ®Google Scholar
• Colussi G, Catena C, Novello M, et al. Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: relevance for cardiovascular outcomes. Nutr Metab Cardiovasc Dis. 2017;27:191–200.
   PubMed Web of Science ®Google Scholar
• Dasilva G, Pazos M, García-Egido E, et al. A lipidomic study on the regulation of inflammation and oxidative stress targeted by marine ω-3 PUFA and polyphenols in high-fat high-sucrose diets. J Nutr Biochem. 2017;43:53–67.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2999–3058.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98:27i–33i.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–1903.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110:368–373.
   PubMed Web of Science ®Google Scholar
• Cunha DNQ, Hamlin RL, Billman GE, et al. N-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling. Brit J Pharmacol. 2007;150:281–285.
   PubMed Web of Science ®Google Scholar
• Leaf A. Omega-3 fatty acids and prevention of arrhythmias. Curr Opin Lipidol. 2007;18:31–34.
   PubMed Web of Science ®Google Scholar
• Wong S, Nestel PJ. Eicosapentaenoic acid inhibits the secretion of triacylglycerol and of apoprotein B and the binding of LDL in Hep G2 cells. Atherosclerosis. 1987;64:139–146.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen X, Fisher EA. N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes. J Clin Invest. 1993;91:1380–1389.
   PubMed Web of Science ®Google Scholar
• Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455–463.
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF, Nguyen MN, et al. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr. 2006;84:37–43.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Are elevated serum triglycerides really a risk factor for coronary artery disease? Cardiology. 2015;131:225–227.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14:401–411.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886–1892.
   PubMed Web of Science ®Google Scholar
• Chivot L, Mainard F, Bigot E, et al. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis. 1990;82:205–211.
   PubMed Web of Science ®Google Scholar
• Luc G, Fievet C, Arveiler D, et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. J Lipid Res. 1996;37:508–517.
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Sansoy V, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168:81–89.
   PubMed Web of Science ®Google Scholar
• Pollin T, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702–1705.
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.
   PubMed Web of Science ®Google Scholar
• TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3:332–340.
   PubMed Web of Science ®Google Scholar
• Maki KC, Bays HE, Dicklin MR, et al. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011;5:483–492.
   PubMed Web of Science ®Google Scholar
• Dunbar RL, Nicholls SJ, Maki KC, et al. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis. 2015;14:98.
   PubMed Web of Science ®Google Scholar
• Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189:19–30.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–992.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–690.
   PubMed Web of Science ®Google Scholar
• Casula M, Soranna D, Catapano AL, et al. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl. 2013;14:243–251.
   PubMed Web of Science ®Google Scholar
• Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 2006;332:752–760.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. London: The Cochrane Collaboration; 2009.
   Google Scholar
• Borenstein M, Hedges L, Higgins J, et al. Comprehensive meta-analysis version 2. Englewood NJ: Biostat; 2005.
   Google Scholar
• Sutton AJ, Abrams KR, Jones DR, et al. Methods for meta-analysis in medical research. NJ, USA: Wiley; 2000.
   Google Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations – a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329–336.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463.
   PubMed Web of Science ®Google Scholar
• Swahn E, von Schenck H, Olsson AG. Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin Drug Investig. 1998;15:473–482.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10:635–645.
   PubMed Web of Science ®Google Scholar
• Bays HE, Hallén J, Vige R, et al. Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial. J Clin Lipidol. 2016;10:181–191.
   PubMed Web of Science ®Google Scholar
• Morton AM, Furtado JD, Lee J, et al. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016;10:1442–1451.
   PubMed Web of Science ®Google Scholar
• Buckley R, Shewring B, Turner R, et al. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr. 2004;92:477–483.
   PubMed Web of Science ®Google Scholar
• Savinova OV, Fillaus K, Harris WS, et al. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. Atherosclerosis. 2015;240:520–525.
   PubMed Web of Science ®Google Scholar
• Skulas-Ray AC, Alaupovic P, Kris-Etherton PM, et al. Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. J Clin Lipidol. 2015;9:360–367.
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF, Mori TA, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest. 2002;32:429–436.
   PubMed Web of Science ®Google Scholar
• Chan DC, Nguyen MN, Watts GF, et al. Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr. 2010;91:900–906.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. A position paper by the Residual Risk Reduction Initiative (R3I). Diabetes Vasc Dis Res. 2008;5:319–335.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–1361.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129:999–1008.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010;24:19–28.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8:94–106.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Colletti A, Bajraktari G, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev. 2017;75:731–767.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation. 2008;118:731–742.
   PubMed Web of Science ®Google Scholar
• Norata GD, Tsimikas S, Pirillo A, et al. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci. 2015;36:675–687.
   PubMed Web of Science ®Google Scholar
• Mazaherioun M, Saedisomeolia A, Javanbakht MH, et al. Beneficial effects of n-3 polyunsaturated fatty acids on adiponectin levels and AdipoR gene expression in patients with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blind clinical trial. Arch Med Sci. 2017;13:716–724.
   PubMed Web of Science ®Google Scholar
• Tai ES, Corella D, Demissie S, et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr. 2005;135:397–403.
   PubMed Web of Science ®Google Scholar
• Olivieri O, Martinelli N, Sandri M, et al. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and “insulin-resistant” T − 455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction. Clin Chem. 2005;51:360–367.
   PubMed Web of Science ®Google Scholar
• Fallaize R, Carvalho-Wells AL, Tierney AC, Marin C, et al. APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the metabolic syndrome. Sci Rep. 2017;7:6274.
   PubMed Web of Science ®Google Scholar
• Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr. 2011;93:243–252.
   PubMed Web of Science ®Google Scholar
• Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–483.
   PubMed Web of Science ®Google Scholar
• Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71:1085–1094.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Campos H, Moye LA, et al. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003;23:853–858.
   PubMed Web of Science ®Google Scholar
• Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation. 2011;124:2065–2072.
   PubMed Web of Science ®Google Scholar
• Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. 2008;102:429–433.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9:531–532.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–571.
   PubMed Web of Science ®Google Scholar
• Pećin I, Nedic M, Reiner Ž. Volanesorsen (ISIS-APOCIII-LRx). Drugs Fut. 2016;41:417–421.
   Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015; 373:438–447.
   PubMed Web of Science ®Google Scholar
• Yang X, Lee SR, Choi YS, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57:706–713.
   PubMed Web of Science ®Google Scholar
• Pechlaner R, Tsimikas S, Yin X, et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 2017;69:789–800.
   PubMed Web of Science ®Google Scholar